Gilbert M. Lenoir

Gilbert M. Lenoir's AcademicInfluence.com Rankings

Gilbert M. Lenoir

Biology

#8707

World Rank

#11828

Historical Rank

Genetics

#877

World Rank

#972

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Gilbert M. Lenoir Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Gilbert M. Lenoir's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. (1998) (2846)
Identification of the breast cancer susceptibility gene BRCA2 (1995) (2451)
Identification of the breast cancer susceptibility gene BRCA2 (1996) (1451)
Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. (1982) (1328)
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 (1993) (1317)
The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. (1996) (1094)
The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. (1994) (1043)
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. (1996) (814)
Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene (1998) (759)
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. (1998) (700)
The human c-myc oncogene: Structural consequences of translocation into the igh locus in Burkitt lymphoma (1983) (600)
Translocations among antibody genes in human cancer. (1983) (569)
Familial breast-ovarian cancer locus on chromosome 17q12-q23 (1991) (532)
Gene expression profiling of primary cutaneous melanoma and clinical outcome. (2006) (481)
Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage (1996) (480)
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma (2011) (459)
Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors (1993) (344)
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families (1996) (313)
Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy (2004) (303)
Geographical prevalence of two types of Epstein-Barr virus. (1986) (288)
Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers (2004) (287)
Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12). (1984) (286)
Predominance of null mutations in ataxia-telangiectasia. (1996) (276)
Acetyl-CoA Carboxylase α Is Essential to Breast Cancer Cell Survival (2006) (275)
Activation and somatic mutation of the translocated c-myc gene in Burkitt lymphoma cells (1984) (263)
Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma (1982) (260)
Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. (1993) (257)
The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. (2002) (255)
An estimate of the heritable fraction of childhood cancer. (1991) (245)
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. (2008) (238)
Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. (1987) (236)
PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. (2004) (230)
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus (1996) (222)
Association between serum trans-monounsaturated fatty acids and breast cancer risk in the E3N-EPIC Study. (2008) (214)
Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. (1992) (209)
Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23 (1990) (197)
Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? (1997) (196)
A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. (1997) (188)
Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. (1999) (182)
Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine. (1998) (180)
A polymorphic stop codon in BRCA2 (1996) (178)
Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene (1991) (177)
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. (1996) (177)
Risk modifiers in carriers of brca1 mutations (1995) (176)
Activation of latent Epstein–Barr virus by antibody to human IgM (1978) (174)
PTEN germ-line mutations in juvenile polyposis coli (1998) (173)
Maternally inherited duplication of the mitochondrial genome in a syndrome of proximal tubulopathy, diabetes mellitus, and cerebellar ataxia. (1992) (170)
European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. (2015) (169)
Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. (2006) (169)
Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. (2000) (168)
Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2 (1999) (160)
Dietary intakes of ω‐6 and ω‐3 polyunsaturated fatty acids and the risk of breast cancer (2009) (157)
Translocation of an immunoglobulin kappa locus to a region 3' of an unrearranged c-myc oncogene enhances c-myc transcription. (1983) (156)
Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein (2002) (154)
PERSISTENT EPSTEIN-BARR VIRUS INFECTION IN A CHILD WITH HYPERGAMMAGLOBULINÆMIA AND IMMUNOBLASTIC PROLIFERATION ASSOCIATED WITH A SELECTIVE DEFECT IN IMMUNE INTERFERON SECRETION (1978) (147)
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. (1998) (145)
Cytogenetic studies on African Burkitt's lymphoma cell lines: t(8;14), t(2;8) and t(8;22) translocations. (1981) (145)
Tumor-specific loss of 11p15.5 alleles in del11p13 Wilms tumor and in familial adrenocortical carcinoma. (1989) (143)
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region (1998) (138)
The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt's lymphoma. (1985) (135)
An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation? (1999) (133)
Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. (1987) (131)
Transcriptional activation of an unrearranged and untranslocated c-myc oncogene by translocation of a C lambda locus in Burkitt. (1983) (131)
RET proto-oncogene mutations in French MEN 2A and FMTC families. (1994) (128)
Screening for germ‐line mutations in the NF2 Gene (1995) (128)
Final case reporting from the ugandan prospective study of the relationship between ebv and burktit's lymphoma (1982) (128)
Aberrant c‐myc RNAs of Burkitt's lymphoma cells have longer half‐lives. (1985) (125)
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. (2009) (124)
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. (1996) (120)
A variant translocation places the λ immunoglobulin genes 3′ to the c-myc oncogene in Burkitt's lymphoma (1984) (120)
BRCA1 Affects Lipid Synthesis through Its Interaction with Acetyl-CoA Carboxylase* (2006) (117)
Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. (1997) (117)
DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study. (1993) (116)
Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: A population‐based study (2003) (115)
A BRCA1 nonsense mutation causes exon skipping. (1998) (115)
Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines (1998) (114)
BRCA1 mutations in Ashkenazi Jewish women. (1995) (114)
Distinctions between endemic and sporadic forms of epstein‐barr virus‐positive burkitt's lymphoma (1985) (110)
Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. (1997) (109)
When Epstein-Barr virus persistently infects B-cell lines, it frequently integrates (1991) (108)
Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma (2011) (107)
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium (2002) (106)
Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype. (1992) (106)
Distinct BRCA1 rearrangements involving the BRCA1 pseudogene suggest the existence of a recombination hot spot. (2002) (106)
Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease. (1998) (105)
Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation. (2000) (105)
Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India (2006) (104)
BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains (2002) (104)
Epidermolytic palmoplantar keratoderma cosegregates with a keratin 9 mutation in a pedigree with breast and ovarian cancer (1994) (104)
Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb. (1992) (102)
Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain (1997) (98)
The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. (2000) (96)
Epstein‐Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma (1986) (94)
[Chromosomal translocation (11; 22) in cell lines of Ewing's sarcoma]. (1983) (93)
Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations (1997) (93)
A novel alteration in the structure of an activated c-myc gene in a variant t(2;8) burkitt lymphoma (1984) (92)
Distribution of androgen and estrogen receptors among lymphoid and haemopoietic cell lines. (1985) (88)
Breakpoints of burkitt's lymphoma t(8;22) translocations map within a distance of 300 kb downstream of MYC (1994) (87)
Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains (1988) (87)
Autocrine growth stimulation of a human T-cell lymphoma line by interleukin 2. (1985) (85)
An Alu‐mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10 (2000) (85)
Expression analysis of endogenous menin, the product of the multiple endocrine neoplasia type 1 gene, in cell lines and human tissues (2000) (84)
Linkage of the multiple endocrine neoplasia type 2B gene (MEN2B) to chromosome 10 markers linked to MEN2A. (1990) (84)
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. (2002) (82)
NF2 gene in neurofibromatosis type 2 patients. (1998) (82)
Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. (1995) (81)
Immunophenotypic and genotypic analysis of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Correlation with histologic features in 36 cases. French Study Group of Pathology for HIV-Associated Tumors. (1994) (80)
Presence of Epstein-Barr virus receptors, but absence of virus penetration, in cells of an Epstein-Barr virus genome-negative human lymphoblastoid T line (Molt 4) (1977) (79)
Selective lack of antibody to a component of EB nuclear antigen in patients with chronic active Epstein-Barr virus infection. (1987) (77)
An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer. (1999) (77)
Regional methylation of the 5’ end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells (2000) (76)
Co‐segregation of MEN2 and Hirschsprung's disease: The same mutation of RET with both gain and loss‐of‐function? (1999) (72)
Burkitt-type lymphoma in France among non-Hodgkin malignant lymphomas in Caucasian children. (1982) (68)
BRAF as a melanoma susceptibility candidate gene? (2003) (67)
Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma [4] (1997) (67)
Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site. (1999) (66)
Replication of Epstein-Barr virus: ultrastructural and immunofluorescent studies of P3HR1-superinfected Raji cells (1977) (65)
Germline brca2 sequence variants in patients with ocular melanoma (1999) (65)
Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA. (1993) (65)
Nonlinkage of 16q markers to familial predisposition to Wilms' tumor. (1992) (64)
BRCA1 and BRCA2 hereditary breast carcinoma phenotypes (1997) (63)
BRCA1 and BRCA2 in Indian breast cancer patients (2002) (63)
Molecular cloning and mapping of a human cDNA (PA2G4) that encodes a protein highly homologous to the mouse cell cycle protein p38-2G4. (1997) (61)
In-situ breast cancer and BRCA 1 (1996) (61)
Treatment of severe Epstein-Barr virus-induced polyclonal B-lymphocyte proliferation by anti-B-cell monoclonal antibodies. Two cases after HLA-mismatched bone marrow transplantation. (1988) (60)
TP53 polymorphism, HPV infection, and risk of cervical cancer. (2001) (60)
BRCA1 and BRCA2 mutation analysis of early‐onset and familial breast cancer cases in Mexico (2002) (60)
A large multisite cancer family is linked to BRCA2. (1995) (57)
Human blymphocytes immortalization by epstein-barr virus in the presence of cyclosporin a (1986) (57)
Neurofibromatosis type 2 appears to be a genetically homogeneous disease. (1992) (57)
Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high-risk area of China. (2001) (57)
MeCP2 and MBD2 expression during normal and pathological growth of the human mammary gland (2002) (56)
Low expression of lymphocyte function-associated antigen (LFA)-1 and LFA-3 adhesion molecules is a common trait in Burkitt's lymphoma associated with and not associated with Epstein-Barr virus. (1990) (56)
Brca2 hereditary breast cancer pathophenotype (1997) (56)
Mutations in the Muscle Sodium Channel Gene (SCN4A) in 13 French Families with Hyperkalemic Periodic Paralysis and Paramyotonia Congenita: Phenotype to Genotype Correlations and Demonstration of the Predominance of Two Mutations (1994) (56)
Increasing incidence of breast cancer in family with BRCA1 mutation (1993) (56)
IL-4 induces LFA-1 and LFA-3 expression on Burkitt's lymphoma cell lines. Requirement of additional activation by phorbol myristate acetate for induction of homotypic cell adhesions. (1989) (56)
Phenotypic analysis of human myeloma cell lines (1989) (55)
c-Ha-ras1 is not deleted in aniridia–Wilms' tumour association (1983) (55)
Lambda Ig constant region genes are translocated to chromosome 8 in Burkitt's lymphoma with t(8;22). (1983) (54)
Correlation Between Serum Phospholipid Fatty Acids and Dietary Intakes Assessed a Few Years Earlier (2009) (54)
Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus. (1993) (53)
Burkitt's lymphoma cell lines reveal different degrees of tumorigenicity in nude mice (1988) (52)
Variable morphology of human immunodeficiency virus-associated lymphomas with c-myc rearrangements. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors, I (1993) (51)
Identification of Epstein-Barr virus terminal protein 1 (TP1) in extracts of four lymphoid cell lines, expression in insect cells, and detection of antibodies in human sera (1990) (51)
Identification of the coding region for a second Epstein‐Barr virus nuclear antigen (EBNA 2) by transfection of cloned DNA fragments. (1985) (50)
Transcriptional Activation of an Unrearranged and Untranslocated c-myc Oncogene by Translocation of a Clambda Locus in Burkitt Lymphoma Cells (1983) (50)
Antibody responses to two Epstein-Barr virus nuclear antigens defined by gene transfer. (1985) (50)
Contribution of BRCA1 and BRCA2 germ‐line mutations to the incidence of breast cancer in young women: Results from a prospective population‐based study in France (2005) (49)
BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma (2007) (49)
A translocated human c-myc oncogene is altered in a conserved coding sequence. (1986) (48)
Paired epstein‐barr virus‐carrying lymphoma and lymphoblastoid cell lines Burkitt's lymphoma patients: Comparative sensitivity to non‐specific and to allo‐specific cytotoxic responses in vitro (1984) (48)
LFA-1, LFA-3, AND ICAM-1 EXPRESSION IN BURKITT'S LYMPHOMA (1987) (48)
Superinfection epithelial nasopharyngeal carcinoma cells with Epstein-Barr virus. (1976) (48)
Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review (2006) (47)
Characterization of an Epstein-Barr virus-induced DNA polymerase (1979) (46)
Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function? (1999) (46)
Epstein-Barr virus (EBV)-containing nasopharyngeal carcinoma cells express the B-cell activation antigen blast2/CD23 and low levels of the EBV receptor CR2 (1989) (45)
Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein‐Barr virus (EBV) (1990) (45)
BRCA1 and BRCA2 sequence variants in Chinese breast cancer families (2002) (44)
Epstein‐barr virus (EBV) nuclear‐antigen‐2‐induced up‐regulation of cd21 and cd23 molecules is dependent on a permissive cellular context (1993) (44)
Identification of eight novel mutations in a collaborative analysis of a part of the second transmembrane domain of the CFTR gene. (1993) (43)
A breast-ovarian cancer susceptibility gene maps to chromosome 17q21. (1993) (43)
Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma‐prone families or patients (2009) (43)
Establishment of lymphomatous cell lines from bone marrow samples from patients with Burkitt's lymphoma. (1984) (43)
Linked markers flanking the gene for multiple endocrine neoplasia type 2A. (1989) (42)
Translocation of oncogene c-sis from chromosome 22 to chromosome 11 in a Ewing sarcoma-derived cell line (1985) (41)
Paired Epstein‐Barr virus (EBV)‐negative and EBV‐converted Burkitt lymphoma lines: Stimulatory capacity in allogeneic mixed lymphocyte cultures (1987) (41)
Epstein-Barr virus markers in a series of Burkitt's lymphomas from the West Nile District, Uganda. (1983) (40)
Infections due to the human herpesviruses in southern India: a seroepidemiological survey. (1986) (40)
Cytogenetic and molecular analysis of 6q deletions in burkitt's lymphoma cell lines (1994) (39)
Variable morphology of human immunodeficiency virus-associated lymphomas with c-myc rearrangements. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors, I. (1993) (39)
Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. (2009) (38)
Serum carotenoid, tocopherol and retinol concentrations and breast cancer risk in the E3N‐EPIC study (2009) (37)
Cell cycle dependence for activation of Epstein-Barr virus by inhibitors of protein synthesis or medium deficient in arginine. (1976) (37)
Epstein-Barr virus associated lymphoproliferative diseases (B cell lymphoma) after transplantation. (1989) (36)
Abdominal Burkitt-type lymphomas in Algeria. (1984) (36)
CDKN2A as a uveal and cutaneous melanoma susceptibility gene (2003) (35)
Histology of BRCA1-associated ovarian tumours (1994) (35)
Antibody response against the Epstein‐Barr virus‐coded nuclear antigen2 (EBNA2) in different groups of individuals (1987) (35)
Clustered somatic mutations in and around first exon of non-rearranged c-myc in Burkitt lymphoma with t(8;22) translocation. (1987) (35)
Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility. (2004) (35)
Presymptomatic diagnosis for neurofibromatosis 2 with chromosome 22 markers (1993) (34)
B-cell maturation stages of Burkitt's lymphoma cell lines according to Epstein-Barr virus status and type of chromosome translocation. (1987) (34)
Characterization of Epstein-Barr virus antigens. I. Biochemical analysis of the complement-fixing soluble antigen and relationship with Epstein-Barr virus-associated nuclear antigen (1976) (34)
Characterisation of 16 polymorphic markers in the NF2 gene: Application to hemizygosity detection (1999) (33)
Occult papillary carcinoma of the thyroid appearing as lung metastasis. (1984) (33)
Phosphofructokinase in human blood cells. (1979) (33)
Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer (2002) (32)
Identification of seven new BRCA1 germline mutations in Italian breast and breast/ovarian cancer families. (1996) (32)
Expression of the second calcitonin/calcitonin gene-related peptide gene in Ewing sarcoma cell lines. (1987) (32)
Epstein-Barr serology in immunodeficiencies: an attempt to correlate with immune abnormalities in Wiskott-Aldrich and Chediak-Higashi syndromes and ataxia telangiectasia. (1984) (32)
The seroepidemiology of infection due to Epstein‐Barr virus in southern India (1985) (32)
Variant translocation in a non endemic case of Burkitt's lymphoma: t (8;22) in an Epstein--Barr virus negative tumour and in a derived cell line. (1981) (32)
A monoclonal antibody with anti‐burkitt lymphoma specificity. I. Analysis of human haematopoietic and lymphoid cell lines (1982) (32)
Gene Array Identification of Epstein Barr Virus-Regulated Cellular Genes in EBV-Converted Burkitt Lymphoma Cell Lines (2002) (31)
No evidence for differences in the Epstein-Barr virus genome carried in Burkitt lymphoma cells and nonmalignant lymphoblastoid cells from the same patients. (1984) (31)
Asymmetric expression of transcripts derived from the shared promoter between the divergently oriented ACACA and TADA2L genes. (2005) (30)
Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin. (1984) (30)
The c-sis oncogene is not activated in Ewing's sarcoma. (1984) (30)
BRCA2 mutations in hereditary breast and ovarian cancer in France. (1997) (30)
Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early‐onset breast and ovarian cancer (2002) (30)
Autoantibodies in three populations of Burkitt's lymphoma patients. (1983) (29)
Mutations clustered in exon 5 of the p53 gene in primary nasopharyngeal carcinomas from Southeastern Asia (1995) (29)
SCREENING MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A FAMILIES USING DNA MARKERS (1988) (29)
Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene (2005) (28)
Measurement of antibodies to varicella-zoster virus in a tropical population by enzyme-linked immunosorbent assay (1984) (28)
Phenotypic characterization of Ewing sarcoma cell lines with monoclonal antibodies (1986) (28)
Expression of P0- and P3-RNA from the normal and translocated c-myc allele in Burkitt's lymphoma cells. (1990) (27)
Linkage analysis of 56 multiplex families excludes the Cowden disease genePTEN as a major contributor to familial breast cancer (1999) (27)
Hereditary breast cancer and family cancer syndromes (2004) (27)
Regional assignment of the ADA locus on 20q13.2→qter by gene dosage studies (1980) (27)
In vitro transforming activity of EBV. I-Establishment and properties of two EBV strains (M81 and M72) produced by immortalized Callithrix jacchus lymphocytes. (1976) (26)
Severe lymphoproliferative disease and Kaposi sarcoma in transplant patients. (1989) (26)
Detection of Epstein-Barr virus genomes in AIDS related lymphomas: sensitivity and specificity of in situ hybridisation compared with Southern blotting. (1991) (26)
Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk (2009) (25)
BRCA1, a gene involved in inherited predisposition to breast and ovarian cancer. (1996) (25)
Cytogenetic studies on Burkitt's lymphoma cell lines. (1983) (25)
Separation and properties of molecular forms of α-galactosidase and α-N-acetylgalactosaminidase from blood lymphocytes and lymphoid cell lines transformed by Epstein-Barr virus (1981) (25)
Enzyme studies on Epstein-Barr virus-transformed lymphoid cell lines from Wolman's disease. Lipases, cholesterol esterase and 4-methylumbelliferyl acyl ester hydrolases. (1984) (24)
EBV‐negative and ‐positive burkitt cell lines variably express receptors for B‐cell activation and differentiation (1986) (24)
Molecular characterization of germline NF2 gene rearrangements. (2000) (23)
Resistance to fludarabine-induced apoptosis in Epstein-Barr virus infected B cells (2002) (23)
Human normal CTL clones: Generation and properties (1983) (23)
BRCA1 and BRCA2 Mutations in Breast and Ovarian Cancer Syndrome: Reflection on the Creighton University Historical Series of High Risk Families (2005) (22)
Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma. (1985) (22)
MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification (2002) (22)
Epstein-Barr virus-specific DNA polymerase in virus-nonproducer Raji cells (1986) (22)
Alternative involvement of two cytogenetically distinguishable breakpoints on chromosome 8 in Burkitt's lymphoma associated translocations. (1986) (22)
Phenotypic analysis of human myeloma cell lines. (1989) (21)
BRCA1 expression during prenatal development of the human mammary gland (1999) (21)
The human insulin-like growth factor-binding protein 4 gene maps to chromosome region 17q12-q21.1 and is close to the gene for hereditary breast-ovarian cancer. (1993) (20)
A 100-kb physical and transcriptional map around the EDH17B2 gene: identification of three novel genes and a pseudogene of a human homologue of the rat PRL-1 tyrosine phosphatase (1995) (20)
Translocations involving Ig-locus-carrying chromosomes: a model for genetic transposition in carcinogenesis. (1982) (20)
The Effect of Mitogens on the Expression of Epstein-Barr Virus Antigens in Human Lymphoid Cell Lines (1979) (20)
Characterization of intermediate filaments expressed by Ewing tumor cell lines. (1987) (20)
Differential activation of cytotoxic responses by Burkitt's lymphoma (BL)-cell lines: relationship to the BL-cell surface phenotype. (1986) (20)
Hereditary medullary thyroid carcinoma: genetic annalysis of three related syndromes. Groupe d'Etude des Tumeurs a Calcitonine. (1989) (19)
Epstein-Barr virus nuclear antigens 1 and 2 in Burkitt lymphoma cell lines containing either 'A'- or 'B'-type virus. (1988) (19)
Multipoint linkage mapping of the Xq25‐q26 region in a family affected by the X‐linked lymphoproliferative syndrome (1989) (19)
A variant translocation places the lambda immunoglobulin genes 3' to the c-myc oncogene in Burkitt's lymphoma. (1984) (19)
EBV‐positive Burkitt's lymphoma from algeria, with a three‐way rearrangement involving chromosomes 2, 8 and 9 (1981) (19)
Abundance of BRCA1 transcripts in human cancer and lymphoblastoid cell lines carrying BRCA1 germ‐line alterations (1997) (19)
Angioimmunoblastic lymphadenopathy after infectious mononucleosis. (1981) (18)
Molecular forms of beta-N-acetylhexosaminidase in Epstein-Barr virus-transformed lymphoid cell lines from normal subjects and patients with Tay-Sachs disease. (1983) (18)
Assignment of the gene for neuroendocrine protein 7B2 (SGNE1 locus) to mouse chromosome region 2[E3-F3] and to human chromosome region 15q11-q15. (1990) (18)
BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations. (2003) (18)
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers. (2005) (18)
Dok1 expression and mutation in Burkitt's lymphoma cell lines. (2007) (17)
A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study (2017) (17)
Upregulation of the BRCA1 gene in human germ cells and in preimplantation embryos. (2005) (16)
Sphingomyelinase and nonspecific phosphodiesterase activities in Epstein-Barr virus-transformed lymphoid cell lines from Niemann-Pick disease A, B and C. (1984) (16)
Genome‐wide search for loss of heterozygosity in Burkitt lymphoma cell lines (2002) (16)
Variant translocation in Burkitt's lymphoma: 8;22 translocation in a French patient with an Epstein-Barr virus-associated tumor. (1981) (16)
The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21. (1994) (16)
Differential recognition of tumor-derived and in vitro Epstein-Barr virus-transformed B-cell lines by fetal calf serum-specific T4-positive cytotoxic T-lymphocyte clones. (1986) (16)
Abnormal expression of vimentin intermediate filaments in human lymphoid cell lines with deletion or translocation of the distal end of chromosome 8. (1984) (16)
New founder germline mutations of CDKN2A in melanoma‐prone families and multiple primary melanoma development in a patient receiving levodopa treatment (2007) (15)
Physical Map and Cosmid Contig Encompassing a New Interstitial Deletion of the X-Linked Lymphoproliferative Syndrome Region (1996) (15)
Alternative pathways of MYCN gene copy number increase in primary neuroblastoma tumors. (2004) (14)
The gene for mannose-binding protein maps to chromosome 10 and is a marker for multiple endocrine neoplasia type 2. (1991) (14)
Molecular Detection of Early-Stage Laryngopharyngeal Squamous Cell Carcinomas (2005) (14)
A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study. (2017) (14)
Cell surface markers on epithelial-Burkitt hybrid cells superinfected with Epstein-Barr virus. (1977) (13)
Differential expression and subcellular localization of murine BRCA1 and BRCA1‐δ11 isoforms in murine and human cell lines (2000) (13)
Expression of the Epstein-Barr virus (EBV) latent membrane protein is tightly regulated, independently of EB nuclear antigen 2 and of EBV integration or copy number. (1993) (13)
Catalase determination in various etiologic forms of Wilms' tumor and gonadoblastoma. (1983) (13)
Expression of CRl and CR2 Complement Receptors following Epstein‐Barr Virus Infection of Burkitt's Lymphoma Cell Lines (1987) (13)
POSSIBLE DUALITY IN BURKITT LYMPHOMA ORIGIN (1984) (13)
Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families (1995) (13)
Haplotype-Based Analysis of Common Variation in the Acetyl-CoA Carboxylase α Gene and Breast Cancer Risk: A Case-Control Study Nested within the European Prospective Investigation into Cancer and Nutrition (2007) (12)
Cryptic exons as a source of increased diversity of Ewing tumor-associated EWS-FLI1 chimeric products. (1999) (12)
X-linked lymphoproliferative syndrome. Identification of a large family in Switzerland. (1988) (12)
Over-expression of lck in Burkitt's lymphoma cell lines. (1991) (11)
Screening for GermLine Rearrangements and Regulatory Mutations in BRCA 1 Led to the Identification of Four New Deletions 1 (1999) (11)
Linkage analysis of hereditary thyroid carcinoma with and without pheochromocytoma (1989) (10)
A new candidate region for the positional cloning of the XLP gene (1998) (10)
Cytology vs molecular analysis for the detection of head and neck squamous cell carcinoma in oesopharyngeal brush samples: a prospective study in 56 patients (2003) (10)
Parameterization of Pb X-Ray Contamination in Simultaneous Tl-201 and Tc-99 m Dual-Isotope Imaging (2009) (10)
Burkitt's lymphoma. Distinction of subgroups by morphometric analysis of the characteristics of 55 cell lines. (1985) (10)
Lysosomal hydrolases in established lymphoid cell lines. (1980) (10)
Limiting dilution cloning of B cells from patients with multiple myeloma: Emergence of non‐malignant B‐cell lines (1989) (9)
NADH cytochrome b5 reductase activity in lymphoid cell lines. Expression of the defect in epstein Barr virus transformed lymphoblastoid cell lines from patients with recessive congenital methemoglobinemia. (1981) (9)
Natural killer cell sensitivity of human lymphoid lines of B-cell origin does not correlate with tumorigenicity or with the expression of certain differentiation markers. (1984) (9)
Are bilateral tumours hereditary? (1991) (9)
BMP7 Expression Correlates with Secondary Drug Resistance in Mantle Cell Lymphoma (2013) (9)
Severe cystic fibrosis in a child homozygous for the G542 nonsense mutation in the CFTR gene. (1993) (9)
Structural analysis of both products of a reciprocal translocation between c-myc and immunoglobulin loci in Burkitt lymphoma. (1985) (9)
CHROMOSOMAL TRANSLOCATIONS IN ALGERIAN BURKITT'S LYMPHOMA (1983) (9)
Ratio of male to female births in the offspring of BRCA1 and BRCA2 carriers (2005) (8)
Structure and regulation of the blast-2/CD23 antigen in epithelial cells from nasopharyngeal carcinoma. (1990) (8)
Virus-induced lymphomas in transplant patients under immunosuppressive therapy. (1987) (8)
Heterozygote BRCA1 status and skewed chromosome X inactivation (2006) (8)
Characterization of Epstein-Barr virus (EBV) antigens II. Detection of early antigen (S) using anticomplement immunofluorescence (ACIF) et complement fixation (CF) tests. (1975) (8)
Gene Expression Pro fi ling of Primary Cutaneous Melanoma and Clinical Outcome (2006) (7)
Elevated NAD(P) glycohydrolase activity: a possible enzymatic marker for malignancy in Burkitt's lymphoma cells. (1982) (7)
Acetyl-CoA carboxylase a gene and breast cancer susceptibility (2004) (7)
Stable expression and function of EBV/C3d receptor following genomic transfection into murine fibroblast L cells (1990) (7)
Effect of chloroquine on Epstein–Barr virus expression (1979) (7)
Localization of the human phosphotyrosine phosphatase-related genes (h-PRL-1) to chromosome bands 1p35–p34, 17q12–q21, 11q24–q25 and 12q24 (1996) (7)
Burkitt's lymphoma variant translocations: distribution of chromosomal breakpoints and perturbated regulation of a mutated c-myc gene. (1988) (7)
TP 53 Polymorphism , HPV Infection , and Risk of Cervical Cancer (2001) (7)
Activated oncogenes in Burkitt's lymphoma. (1984) (6)
[Cancer genetic predisposition: current events and perspectives 2005]. (2005) (6)
Retroviral transduction of splice variant Brca1-Δ11 or mutant Brca1-W1777Stop causes mouse epithelial mammary atypical duct hyperplasia (2002) (6)
Expression of CR1 and CR2 complement receptors following Epstein-Barr virus infection of Burkitt's lymphoma cell lines. (1987) (6)
Physical Mapping of Xq24–25 around Loci Closely Linked to the X-Linked Lymphoproliferative Syndrome Locus: An Overlapping YAC Map and Linkage between DXS12, DXS42, and DXS37 (1993) (6)
Epstein-Barr virus-epithelial cell interaction and its implication in the etiology of nasopharyngeal carcinoma. (1978) (6)
[Translocations t(2;8) and t(8;22) in continuous cell lines of African Burkitt's lymphoma]. (1980) (6)
Genetic analysis of 24 French families with multiple endocrine neoplasia type 2A. (1992) (6)
Immunologic markers of Burkitt's lymphoma cells. (1985) (5)
Workshop on ataxia-telangiectasia heterozygotes and cancer. (1985) (5)
Molecular characterization of the Epstein-Barr virus DNA in three new Burkitt's lymphoma-derived cell lines. (1984) (5)
Burkitt's lymphoma : a human cancer model : proceedings of a symposium (1985) (5)
Validity of lymphoid cell line for enzymatic studies of GM2-gangliosidosis variant 0 (Sandhoff disease). (1985) (5)
[Chromosome translocations and Epstein-Barr virus in Burkitt's lymphoma]. (1987) (5)
HTLV‐I‐positive case of ATL in Georgia (formerly USSR) (1992) (5)
Inhibition of HSV-1 multiplication in rat embryo fibroblasts constitutively expressing the EJ-ras oncogene. (1990) (5)
Workshop on linkage studies of hereditary breast cancer. (1990) (5)
Autoantibodies in Burkitt's lymphoma patients from the Ugandan prospective study. (1986) (4)
Cytogenetic evaluation of bone marrow involvement in Burkitt's lymphoma. (1988) (4)
[Analysis of the RET gene and medullary cancer of the thyroid. Contribution to the diagnosis and treatment]. (1996) (4)
Individualisation pathogénique du lymphome de Burkitt en France. (1980) (4)
t(2;8) variant translocation in burkitt's lymphoma: Mapping of chromosomal breakpoints by in situ hybridization (1989) (4)
Epstein-Barr virus terminal protein gene transcription is dependent on EBNA2 expression and provides evidence for viral integration into the host genome. (1990) (4)
Expression of c-fgr in EBV positive and negative B cell tumors. (1989) (4)
Common BRCA 2 Variants and Modification of Breast and Ovarian Cancer Risk in BRCA 1 Mutation Carriers (2005) (4)
Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort. (2006) (4)
High frequency of-β-hexosaminidase deficiency in lymphoblastoid cell lines (1984) (4)
CD23 and epithelial cells. (1991) (4)
A new Epstein-Barr virus negative Burkitt's lymphoma derived cell-line. I. Analysis of cell surface markers and abnormal expression of HLA antigens. (2008) (3)
Induction of Epstein-Barr virus early antigen by phytohaemagglutinin in the presence of 5-iodo-2'-deoxyuridine: application to EBV serology. (1980) (3)
Separation and properties of molecular forms of alpha-galactosidase and alpha-N-acetylgalactosaminidase from blood lymphocytes and lymphoid cell lines transformed by Epstein-Barr virus. (1981) (3)
[Lymphoproliferative syndromes associated with Epstein-Barr virus in transplantation]. (1992) (3)
Variable expressivity of Familial Medullary Thyroid Carcinoma (FMTC) due to a RET V804M (GTGG→ATG) mutation in two families: Reluctance of gene carriers to accept prophylactic thyroidectomy (1999) (3)
[Burkitt's lymphoma and Epstein-Barr virus]. (1979) (3)
NADH-Cytochrome b 5 Reductase Activity in Lymphoid Cell Lines EXPRESSION OF THE DEFECT IN EPSTEIN-BARR VIRUS TRANSFORMED LYMPHOBLASTOID CELL LINES FROM PATIENTS WITH RECESSIVECONGENITAL METHEMOGLOBINEMIA (3)
Dietary intakes of x-6 and x-3 polyunsaturated fatty acids and the risk of breast cancer (2009) (3)
Erratum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma (Nature (2011) 480:94-98 doi:10.1038/nature10539) (2016) (3)
Burkitt’s lymphoma: Multiparametric analysis of 55 cell lines with special reference to morphometry (1985) (3)
Genetic screening of endocrine tumour syndromes with DNA probes: the example of medullary thyroid carcinoma. (1989) (3)
[Cancer genetic predisposition: current events and perspectives in 2010]. (2010) (2)
Differential expression and subcellular localization of murine BRCA1 and BRCA1-delta 11 isoforms in murine and human cell lines. (2000) (2)
BRCA 1 Wild-Type Allele Modifies Risk of Ovarian Cancer in Carriers of BRCA 1 GermLine Mutations 1 (2003) (2)
Immunoblastic lymphoma following Hodgkin's disease: a case report with translocation t(8;14) in tumoral cells and sporadic t(7;14) in peripheral lymphocytes. (1985) (2)
[Fatal primary Epstein-Barr virus infections with or without infectious mononucleosis (author's transl)]. (1981) (2)
Endocytosis of class II histocompatibility antigens and formation of intracytoplasmic granules at the final differentiation stage of human B lymphocytes. (1983) (2)
Studies on Epstein-Barr virus DNA polymerase activities in various human lymphoblastoid cell lines. (1978) (2)
Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma (2015) (2)
Letter: In vitro induction of EBV early antigens in NPC epithelial tumour cells by IUDR or superinfection. (1975) (2)
Epstein-Barr virus (EBV) antigenic determinants on subunits of the EBV determined nuclear antigen (EBNA). (1980) (2)
Epstein-Barr virus and rheumatoid arthritis: are rheumatoid arthritis associated nuclear antigen and Epstein-Barr virus nuclear antigen different? (1982) (2)
Herpes simplex type 1 activation by Epstein-Barr virus nuclear antigen 1. (1990) (2)
A preliminary analysis of consortium data for markers tightly linked to multiple endocrine neoplasia type 2A. (1992) (2)
[Lymphoblastoid cell lines transformed by the Epstein-Barr virus. Cellular model in culture for the study of lysosomal enzyme disorders]. (1983) (2)
Early detection of hereditary medullary thyroid cancer with polymorphic DNA probes. Groupe d'Etude des Tumeurs a Calcitonine. (1989) (2)
Hypokalemic Periodic Paralysis andtheDihydropyridine Receptor (CACNLIA3):Genotype/Phenotype Correlations forTwo Predominant Mutations andEvidence fortheAbsenceofa Founder Effect in16Caucasian Families (1995) (1)
Triplex gene dosage effect of TPI and G3PD in a human lymphoblastoid cell line with partial trisomy 12p13 and 18p (1979) (1)
Cooperation between cellular and Epstein-Barr virus genes in the genesis of Burkitt's lymphoma. (1988) (1)
Analysis of Ewing Tumour with Panels of Monoclonal Antibodies (1985) (1)
Epstein-Barr virus-associated Burkitt's lymphoma in India. (1983) (1)
[Pathogenic characterization of Burkitt's lymphoma in France. What is the problem? How to resolve it? Preliminary results. Role of cytogenetic abnormalities]. (1980) (1)
[Genetics of neurofibromatosis: recent progress and prospects]. (1991) (1)
[Neural crest and multiple endocrinopathies]. (1996) (1)
[Epstein-Barr virus and infectious mononucleosis. A clinical study of Epstein-Barr antibodies (author's transl)]. (1978) (1)
MeCP 2 and MBD 2 expression during normal and pathological growth of the human mammary gland (2019) (1)
Endemic and sporadic cases of Epstein-Barr virus-positive Burkitt's lymphoma: immunological characterization of derived cell lines. (1985) (1)
The gene for MEN 2A is tightly linked to the centromere of chromosome 10 (1991) (1)
[Correlation between variant translocation and the expression of immunoglobulin light chains in Burkitt-type lymphomas and leukemias]. (1981) (1)
Epstein-Barr virus nuclear antigen (EBNA)-positive cells in a lymph-node of a child with severe primary EBV infection. (1978) (1)
Indication for bone-marrow harvesting and purging in Burkitt's Lymphoma: a three-year experience. (1985) (1)
Regional assignment of the ADA locus on 20q13.2 leads to qter by gene dosage studies. (1980) (1)
[Familial medullary thyroid cancer. Contribution of genealogy and genetics to the study of two families]. (1990) (0)
Translocation ofthec-mncgeneintotheimmunoglobulin heavy chain locus inhumanBurkitt lymphoma andmurine plasmacytoma cells (1982) (0)
[Predictive tests for familial medullary cancer of the thyroid]. (1992) (0)
Nucleic Acids Research Clustered somatic mutations in and around first exon of non-rearranged c-myc in Burkitt lymphoma with t(8;22) transiocation (2005) (0)
Table of Contents (1993) (0)
Tumorigenic Potential of Various Burkit’s Lymphoma Cell Lines in Nude Mice (1987) (0)
Deletions Led to the Identification of Four New BRCA 1 Mutations in Screening for GermLine Rearrangements and Regulatory Updated Version (1999) (0)
Metastatic capacity of Burkitt's lymphoma cell lines in nude mice. (1992) (0)
Immunoglobulin secretion by Burkitt's lymphoma cell lines. (1984) (0)
Changes in microRNAs spectrum during melanoma progression (2006) (0)
[Strict correlation between anti-RANA antibodies and anti-EBNA antibodies apart from rheumatoid arthritis. Assessment of the diagnostic value of anti-RANA antibody]. (1983) (0)
[Recent data on the pathogenic role of the Epstein-Barr virus]. (1978) (0)
Hereditary Medullary Thyroid Carcinoma: Genetic Analysis of Three Related Syndromes (2020) (0)
[Immunodeficiency and cancer]. (1989) (0)
Detection ofEpstein-Barr virus genomes inAIDS related lymphomas: Sensitivity andspecificity ofin situ hybridisation comparedwithSouthern blotting (1991) (0)
Epstein-Barr virus ( EBV ) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells ( herpesvirus / nuclear antigens / cell growth / transformation ) (2003) (0)
Absence of major germline gene rearrangements in c-myc and L-myc in children with malignancies (1990) (0)
[Genetic predisposition to cancer development]. (1995) (0)
[Theory and practice of the serology of Epstein-Barr virus]. (1982) (0)
[Cytogenetic markers and Burkitt-type malignant lymphomas]. (1983) (0)
Complexes moleculaires brca1/acc alpha, applications diagnostiques et therapeutiques (2002) (0)
BRCA 1 expression during prenatal development of the human mammary gland (2019) (0)
[Prometaphase cytogenetic study of 13 cases of Wilms' tumor without aniridia]. (1983) (0)
[Heredity and medullary cancer of the thyroid]. (1990) (0)
Expression of Epstein-Barr Virus Latent Genes and Evidence for Integration of Viral DNA into the Host Genome in Burkitt’s Lymphoma Cells (1990) (0)
Analysis of N-myc oncogene in neuroblastoma cells from 53 patients (1989) (0)
The effects of mitogens on the expression of Epstein-Barr virus antigens in human lymphoid cell lines. (1979) (0)
ABUNDANCE OF BRCA 1 TRANSCRIPTS IN HUMAN CANCER AND LYMPHOBLASTOID CELL LINES CARRYING BRCA 1 GERMLINE ALTERATIONS (2018) (0)
A Monoclonal Antibody Defining a Burkitt Lymphoma Associated Antigen (1982) (0)
Induction of B Cell Activation Markers by Epstein-Barr Virus (1988) (0)
Epstein-Barr Virus Serology: Specificities of Sera Against EBNA 1 and EBNA 2 (1987) (0)
[Burkitt's lymphoma in 1985]. (1985) (0)
Immunophenotypic classification of 28 Burkitt cell lines with monoclonal antibodies and reagent selection for bone-marrow purging. (1985) (0)
[Molecular analysis of biopsies of bronchial cancers: feasibility of a systematic approach]. (1989) (0)
DNA-Mediated Gene Transfer of Epstein-Barr Virus Receptor onto Murine Fibroblasts (1988) (0)
Polymorphism of Human Oncogenes and Cancer Susceptibility (1985) (0)
Pharmacogenetic Study in Hodgkin’s Lymphomas, Impact of UGT1A1 on Prognosis. (2006) (0)
Translocation of the c-mnc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells ( recombination / chromosome / cancer / DNA ) (0)
Cancer Research in France (1927) (0)
[Revocation of the BRCA1 patents by the European Office of Patents: a victory over a rights abuse]. (2005) (0)
Combinatorial generation ofvariable fusion proteins in theEwingfamily oftumours (1993) (0)
[An all-inclusive genetic theory for carcinogenesis?]. (1984) (0)
Addendum to the minireview Chromosome microdissection: a brief overview (1997) (0)
[Genetic predisposition to cancer: familial forms of medullary thyroid cancer and breast cancer]. (1994) (0)
High frequency of beta-hexosaminidase deficiency in lymphoblastoid cell lines. (1984) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Gilbert M. Lenoir?

Gilbert M. Lenoir is affiliated with the following schools:

Gilbert M. Lenoir's Academic­Influence.com Rankings

Why Is Gilbert M. Lenoir Influential?

Gilbert M. Lenoir's Published Works

Published Works

What Schools Are Affiliated With Gilbert M. Lenoir?

Gilbert M. Lenoir's AcademicInfluence.com Rankings